- Strategic Partnership to Support Facility Design and Digital Infrastructure Implementation
- Accelerates Development of State-of-the-Art Advanced Therapy Manufacturing Technologies
- Enhances Operational Excellence for Clinical-to-Commercial Manufacturing Capabilities
, /PRNewswire/ — BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), today announced a strategic partnership with Orchestra Life Sciences (OLS), a premier technical consultancy firm specializing in advanced therapy manufacturing solutions. This collaboration supports BioCentriq’s recently announced expansion in Princeton, New Jersey, and focuses on BioCentriq’s $12M CAPEX investment for facility optimization and digital integration to enhance the site’s cell therapy development, GMP manufacturing, and testing capabilities, while delivering a customer-ready facility that upholds the highest standards of operational excellence and quality.
Orchestra Life Sciences will provide comprehensive technical expertise and strategic support for BioCentriq’s new 60,000 sq. ft. Princeton facility, announced in December 2024. The partnership encompasses multiple strategic initiatives, including the implementation of advanced manufacturing technologies, development of a fully integrated digital ecosystem, and optimization of facility design to meet the stringent regulatory requirements of …